

**Amendments to the Claims:**

1-4. cancelled.

5. (previously presented) The compound of claim 27 wherein:

substituent(s) on E is(are) independently substituted or unsubstituted alkyl, halogen, hydroxy, ester, -S-alkyl, NO<sub>2</sub> or SO<sub>2</sub>;

substituent(s) on G is(are) independently substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, halogen, amide, amine, hydroxy, sulfonyl, sulfonamide, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-amine, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-heterocycle, or -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-amide, wherein n and m are independently 0, 1, 2, 3, 4 or 5; and

substituent(s) on J is(are) independently substituted or unsubstituted alkyl, halogen, ether, -S-alkyl, or -S-aryl.

6. (original) The compound of claim 5, wherein:

substituent(s) on E and J is(are) halogen; and

substituent(s) on G is(are) halogen and/or substituted alkyl.

7-19 (cancelled)

20. (previously presented) A composition comprising a compound according to claim 27 in a pharmaceutically acceptable carrier therefor.

21. (currently amended) A method of modulating the level of Amyloid Beta ~~Precursor~~ Protein (APP), said method comprising contacting ~~said protein~~ Amyloid Beta Precursor Protein (APP) with at least one compound according to claim 27.

22. (original) A method according to claim 21, wherein said APP is APP<sub>751</sub>, APP<sub>695wt</sub>, APP<sub>670/671</sub>, APP<sub>670/671/717</sub>, sAPP, α-sAPP, or β-sAPP.


23. (currently amended) A method for treating disease conditions resulting from production of amyloid  $\beta$ , said method comprising administering to a patient having a said disease condition a therapeutically effective amount of at least one compound according to claim 27.

24. (original) A method according to claim 23, wherein said disease condition is amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, an Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, and Down's syndrome.

25. (currently amended) A method for preventing disease conditions resulting from production of amyloid  $\beta$  in a subject at risk thereof, said method comprising administering to said subject a therapeutically effective amount of at least one compound according to claim 27.

26. (currently amended) A method for treating a subject in need thereof to decrease production of  $A\beta$  amyloid  $\beta$ , said method comprising administering to said subject an effective amount of the compound according to claim 27.

27. (currently amended) A compound having the structure:



and pharmaceutically acceptable salts thereof, wherein:

**D** is hydrogen or lower alkyl;

**E** is substituted or unsubstituted phenyl;

**G** is substituted or unsubstituted phenyl; and

**J** is substituted ~~or unsubstituted~~ phenyl, comprising one or more substituents selected from the group consisting of methyl, substituted alkyl, halogen, ether, -S-alkyl, or -S-aryl.

Applicant: Smith et al.

Application No: 09/890,927

Docket No: 1188-67 PCT/US

Page 4

28. (new) A method of modulating the proteolytic cleavage of APP comprising the step of contacting said APP with at least one compound of claim 27.